Cooper Companies Sees Unusually High Options Volume (NASDAQ:COO)

Key Points

• Unusual options activity: Traders purchased 2,270 Cooper Companies call options, about 121% above the typical daily volume of 1,026.
• Analyst sentiment remains cautious: The stock has a consensus “Hold” rating from MarketBeat, with a consensus price target of $68.60; ratings range from Buy to Sell.
• Insiders and the company showed confidence: Insiders bought 34,701 shares worth approximately $1.88 million in the last quarter, while Cooper Companies authorized a $3 billion share-repurchase plan covering up to 22.7% of outstanding shares.

The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders bought 2,270 call options on the company. This represents an increase of approximately 121% compared to the typical daily volume of 1,026 call options.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on COO shares. Piper Sandler restated a "neutral" rating on shares of Cooper Companies in a report on Thursday, October 15th. Zacks Research lowered shares of Cooper Companies from a "hold" rating to a "strong sell" rating in a research note on Friday, September 11th. Barclays upgraded shares of Cooper Companies to a "hold" rating in a research report on Wednesday, October 7th. Needham & Company LLC lowered their target price on shares of Cooper Companies from $86.00 to $73.00 and set a "buy" rating for the company in a research note on Thursday, September 10th. Finally, Citigroup reissued a "neutral" rating and set a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $68.60.

Insider Buying and Selling at Cooper Companies

In related news, Director Paul Keel purchased 4,701 shares of the firm's stock in a transaction dated Friday, September 11th. The stock was bought at an average price of $53.18 per share, with a total value of $249,999.18. Following the completion of the purchase, the director owned 4,701 shares in the company, valued at approximately $249,999.18. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence Kurzius acquired 10,000 shares of the stock in a transaction dated Wednesday, September 16th. The shares were bought at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the transaction, the director directly owned 31,099 shares of the company's stock, valued at $1,708,268.07. The trade was a 47.40% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 34,701 shares of company stock worth $1,880,039. Insiders own 2.08% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Avalon Trust Co acquired a new position in shares of Cooper Companies during the second quarter valued at about $25,000. SJS Investment Consulting Inc. increased its position in shares of Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock worth $26,000 after acquiring an additional 187 shares in the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock worth $29,000 after acquiring an additional 375 shares during the last quarter. Continuum Advisory LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter worth about $30,000. Finally, J.Safra Asset Management Corp acquired a new stake in shares of Cooper Companies in the 2nd quarter worth about $32,000. Institutional investors and hedge funds own 24.39% of the company's stock.

Cooper Companies Trading Down 1.7%

COO stock traded down $1.07 during mid-day trading on Friday, reaching $60.58. The company's stock had a trading volume of 238,058 shares, compared to its average volume of 2,712,205. Cooper Companies has a 12 month low of $51.01 and a 12 month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The business's 50 day moving average price is $62.09 and its 200 day moving average price is $65.80. The company has a market cap of $11.52 billion, a price-to-earnings ratio of 20.67, a price-to-earnings-growth ratio of 2.40 and a beta of 0.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the previous year, the business posted $0.49 EPS. Cooper Companies's revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities research analysts predict that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has approved a share buyback plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women's health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.